Evidence map›Paper›PMID 24411578›Full record

ArticleOphthalmology2014

Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications.

Afshan A Nanji, Christina S Moon, Anat Galor, Julia Sein, Patrick Oellers, Carol L Karp

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 1 synthesis or guideline pooled it, 136 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Infectious etiologies of conjunctival tumors.Expert review of ophthalmology · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. The Management of Ocular Surface Squamous Neoplasia (OSSN).International journal of molecular sciences · 2022
    Review
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Afshan A NanjiBascom Palmer Eye Institute, University of Miami, Miami, Florida.
Christina S MoonBascom Palmer Eye Institute, University of Miami, Miami, Florida.
Anat GalorBascom Palmer Eye Institute, University of Miami, Miami, Florida.
Julia SeinBascom Palmer Eye Institute, University of Miami, Miami, Florida.
Patrick OellersBascom Palmer Eye Institute, University of Miami, Miami, Florida.
Carol L KarpBascom Palmer Eye Institute, University of Miami, Miami, Florida. Electronic address: ckarp@med.miami.edu.
Miami Dermatology and Laser Institute · USUniversity of Miami · US

Funding

Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Victor L Perez · 2004 to 2026
$12.2M
NEI NIH HHS P30 EY014801NEI NIH HHS P30EY014801
6 · The paper itself

Abstract

purposeTreatment for ocular surface squamous neoplasia (OSSN) has historically been surgery, but nonsurgical interventions are increasingly used. Treatment with interferon is efficacious, but evidence is needed regarding recurrence and complication rates in comparison with surgery. The objective of this study is to compare the recurrence and complication rates of surgical treatment and interferon treatment for OSSN.

designA matched, case-control study.

participantsNinety-eight patients with OSSN, 49 of whom were treated with interferon (IFN) α2b therapy and 49 of whom were treated with surgical intervention.

methodsPatients with OSSN were treated with surgery versus IFNα2b therapy, either in topical or injection form. Median follow-up after lesion resolution was 21 months (range, 0-173 months) for the IFNα2b group and 24 months (range, 0.9-108 months) for the surgery group.

main outcome measuresThe primary outcome measure for the study was the rate of recurrence of OSSN in each of the treatment groups. Recurrence rates were evaluated using Kaplan-Meier survival analysis.

resultsMean patient age and sex were similar between the groups. There was a trend toward higher clinical American Joint Committee on Cancer tumor grade in the IFNα2b group. Despite this, the number of recurrences was equal at 3 per group. The 1-year recurrence rate was 5% in the surgery group versus 3% in the IFNα2b group (P = 0.80). There was no statistically significant difference in the recurrence rate between the surgically and medically treated groups. Nonlimbal location was a risk factor for recurrence (hazard ratio, 8.96) in the entire study population. In patients who were treated successfully, the side effects of the 2 treatments were similar, with mild discomfort seen in the majority of patients in both groups. There was no limbal stem cell deficiency, symblepharon, or diplopia noted in either group. Two patients were excluded from the IFNα2b group because of intolerance to the medication.

conclusionsNo difference in the recurrence rate of OSSN was found between surgical versus IFNα2b therapy.

Indexed as

Ophthalmologic Surgical ProceduresAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma in SituCarcinoma, Squamous CellCase-Control StudiesConjunctival NeoplasmsCorneal DiseasesCryotherapyEye NeoplasmsFemaleHumansInterferon-alphaInterferon alpha-2Antineoplastic AgentsInterferon-alphaInterferon alpha-2Ophthalmic SolutionsRecombinant Proteins

Identifiers

PMID24411578
PMCPMC4011994
OpenAlexW2592933953

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.